WO2008033910A3 - Punctum: drug delivery site for therapeutic peptides and proteins - Google Patents

Punctum: drug delivery site for therapeutic peptides and proteins Download PDF

Info

Publication number
WO2008033910A3
WO2008033910A3 PCT/US2007/078256 US2007078256W WO2008033910A3 WO 2008033910 A3 WO2008033910 A3 WO 2008033910A3 US 2007078256 W US2007078256 W US 2007078256W WO 2008033910 A3 WO2008033910 A3 WO 2008033910A3
Authority
WO
WIPO (PCT)
Prior art keywords
punctum
lacrimal
proteins
drug delivery
drug
Prior art date
Application number
PCT/US2007/078256
Other languages
French (fr)
Other versions
WO2008033910A2 (en
Inventor
Josefino B Tunac
Jaime V Aragones
Original Assignee
Josefino B Tunac
Jaime V Aragones
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Josefino B Tunac, Jaime V Aragones filed Critical Josefino B Tunac
Publication of WO2008033910A2 publication Critical patent/WO2008033910A2/en
Publication of WO2008033910A3 publication Critical patent/WO2008033910A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Abstract

Disclosed is an. alternate route for drug delivery, which involves the punctum. The lacrimal punctum is an opening in the corner of the eye through which tears drain into the nasolacrimal duct, a highly vascularized collection system. Delivering therapeutic peptides or proteins into the punctum allows the drug to 'be naturally absorbed into the lacrimal vascularization for systemic distribution into the bloodstream. Since the punctum is a natural opening, this would constitute a painless route for drag administration. In one embodiment, SOD is introduced into the punctum and absorbed intact into the blood stream without antigenic or unwanted allergic reaction. The drug absorption site could start in the punctum and continue on to the canaliculi, lacrimal sac, ami nasolacrimal drainage system, to the nasal meatus. Also, diffusion to the highly vascularized choroids may occur due to proximity oi'the punctum to ihti lacrimal lake.
PCT/US2007/078256 2006-09-12 2007-09-12 Punctum: drug delivery site for therapeutic peptides and proteins WO2008033910A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84378506P 2006-09-12 2006-09-12
US60/843,785 2006-09-12

Publications (2)

Publication Number Publication Date
WO2008033910A2 WO2008033910A2 (en) 2008-03-20
WO2008033910A3 true WO2008033910A3 (en) 2008-11-13

Family

ID=39184544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078256 WO2008033910A2 (en) 2006-09-12 2007-09-12 Punctum: drug delivery site for therapeutic peptides and proteins

Country Status (1)

Country Link
WO (1) WO2008033910A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115282127B (en) * 2022-04-21 2023-08-29 广州医科大学附属第二医院 Chitosan calcium alginate nanoparticle microsphere and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same

Also Published As

Publication number Publication date
WO2008033910A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
Tangri et al. Basics of ocular drug delivery systems
US10925889B2 (en) Method of treating, reducing, or alleviating a medical condition in a patient
JP5290167B2 (en) Puncture plug for active agent delivery
US20080045911A1 (en) Punctal plugs for the delivery of active agents
Shakya et al. Palatal mucosa as a route for systemic drug delivery: A review
JP5415262B2 (en) Puncture plug for active agent delivery
JP2009501797A5 (en)
Taskar et al. Advances in the use of prodrugs for drug delivery to the eye
WO2013030679A3 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
WO2004073551A3 (en) Transscleral drug delivery device and related methods
WO2007011880A3 (en) Enhanced ocular neuroprotection/neurostimulation
DE60214697D1 (en) DEVICE FOR RELEASING AN OPHTHALMIC MEDICINAL PRODUCT
WO2006082588A3 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
US11648261B2 (en) Method of treating, reducing, or alleviating a medical condition in a patient
WO2009137085A8 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
AR039130A2 (en) METHOD OF ADMINISTRATION OF A PHARMACEUTICALLY ACTIVE AGENT WITH A HUMAN EYE
WO2006091332A3 (en) Intranasal administration of active agents to the central nervous system
WO2007022541A3 (en) Method of treating dry eye disease with non-drying antihistamines
JP5259130B2 (en) Puncture plug for administration of active agent
JP2008049129A (en) Lacrimal punctum plug for delivery of active agent
El Hoffy et al. Glaucoma: management and future perspectives for nanotechnology-based treatment modalities
US20070117750A1 (en) Method for enhanced ocular drug penetration
WO2008033910A3 (en) Punctum: drug delivery site for therapeutic peptides and proteins
US20020139378A1 (en) Method for creating a separation of posterior cortical vitreous from the retina of the eye
Vyas et al. Ocular delivery of peptides and proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07814825

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07814825

Country of ref document: EP

Kind code of ref document: A2